Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.57 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.57 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.57 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 6/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10291433 | 0.91 | LRRK2 (0.56) | LRRK2GSK3AMAPK15CAMKK2GLO1 | |
| SCHEMBL10012141 | 0.91 | GLO1 (0.60) | LRRK2GSK3AMAPK15CAMKK2GLO1 | |
| SCHEMBL10012115 | 0.91 | GLO1 (0.56) | LRRK2GSK3AMAPK15CAMKK2GLO1 | |
| SCHEMBL625786 | 0.90 | GLO1 (0.62) | LRRK2GSK3AMAPK15CAMKK2GLO1 | |
| SCHEMBL10291751 | 0.90 | LRRK2 (0.58) | LRRK2GSK3AMAPK15CAMKK2GLO1 | |
| SCHEMBL1460540 | 0.90 | MAPK3 (0.63) | LRRK2PTK2MAPK3EGFRMET | |
| SCHEMBL1460536 | 0.88 | GLO1 (0.61) | LRRK2GSK3AMAPK15CAMKK2GLO1 | |
| SCHEMBL1708502 | 0.85 | GLO1 (0.65) | LRRK2GSK3AMAPK15CAMKK2GLO1 | |
| SCHEMBL1706896 | 0.85 | LRRK2 (0.68) | LRRK2GSK3AMAPK15CAMKK2GLO1 | |
| SCHEMBL1037328 | 0.84 | GLO1 (0.63) | LRRK2GSK3AMAPK15CAMKK2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | claimed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | claimed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | claimed |
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | LRRK2 1037/4885GSK3A 556/4885MAPK15 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.